Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
The Cooper Companies, Inc. (COO) is highlighted as a strong buy due to its market-share gains in CooperVision, leadership in myopia management with MiSight, and the recovery of CooperSurgical's fertility segment. Despite challenges like weakness in the Asia-Pacific market and margin pressures from tariffs and foreign exchange, the company's long-term growth opportunities remain robust. Cooper Companies has consistently beaten earnings estimates, reinforcing its positive outlook.
Here's Why You Should Add Cooper Companies Stock to Your Portfolio Now
Cooper Companies (COO) shows strong growth potential due to CooperVision's premium lens and myopia-management leadership, coupled with CooperSurgical's robust women's health and fertility segments. Despite near-term challenges like Asia-Pacific weakness and tariff/FX pressures, the company's sustained market-share gains and high-growth franchises position it favorably. Analysts maintain a positive outlook, with expectations of improved earnings and revenue growth in the coming fiscal years.
Citigroup Adjusts Cooper Companies PT to $80 From $76, Maintains Neutral Rating
Citigroup has adjusted its price target for The Cooper Companies (COO) to $80 from $76, while maintaining a Neutral rating on the stock. This update reflects a change in the analyst's outlook for the medical device company. Other recent analyst actions for Cooper Companies include UBS initiating coverage with a Neutral rating and Rothschild & Co Redburn adjusting its price target.
Here's Why You Should Add BrightSpring Stock to Your Portfolio Now
BrightSpring Health Services (BTSG) is identified as a strong buy due to robust growth in Provider Services and specialty/infusion operations, successful integration of acquired assets, and a scalable home-based care platform. Despite potential headwinds from the Inflation Reduction Act and brand-to-generic conversions, the company's shares have significantly outperformed the industry and S&P 500 year-to-date. Analysts expect strong earnings and revenue growth for 2026, making it a compelling addition to an investment portfolio.
NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based clinical decision-support tools and progress in its idiopathic generalized epilepsy program, signaling continued innovation and market expansion.
Alcon’s New-Product Wave Carries Q2 As It Walks Away From Accommodating IOL Bet
Alcon's Q2 performance was boosted by new product introductions, a strategy that comes as the company anticipates a $60 million refund from the US government. Alcon plans to reinvest approximately two-thirds of this refund back into its business operations. This move also signifies Alcon's shift away from its bet on accommodating intraocular lenses (IOLs).
Mizuho raises Alcon stock price target to $85 on new products
Mizuho has increased its price target for Alcon Inc. (NYSE:ALC) shares from $80 to $85, maintaining an Outperform rating, due to anticipated new product growth from Unity VCS and Tryptyr in Q2 2026. Despite headwinds in certain divisions like Implantables, Panoptix Pro share gains are providing an offset, and the firm expects continued strong performance from its ophthalmology portfolio. Alcon recently reported strong Q2 fiscal 2026 results and engaged in strategic collaborations, reinforcing its position in the medtech market.
Cardinal Health (CAH) Q4 Earnings Beat Estimates
Cardinal Health (CAH) reported Q4 earnings of $2.91 per share, surpassing the Zacks Consensus Estimate of $2.42, marking a 20.25% surprise. While earnings beat expectations, the company's revenues of $63.67 billion missed the consensus estimate
Assenagon Asset Management S.A. Buys 457,938 Shares of The Cooper Companies, Inc. $COO
Assenagon Asset Management S.A. significantly increased its stake in The Cooper Companies (NASDAQ:COO) by 674.1% in the second quarter, purchasing 457,938 additional shares to own a total of 525,872 shares valued at $37.7 million. This move is part of a broader trend of institutional investment, with several other major funds also expanding their positions, bringing total institutional ownership to 24.39%. The Cooper Companies recently surpassed quarterly earnings and revenue estimates, reporting $1.21 EPS and $1.08 billion in revenue, while analysts maintain a consensus "Hold" rating with an average price target of $81.36.
The Cooper Companies, Inc. $COO Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 1.5% in the first quarter, selling 22,431 shares but still retaining a significant holding of 1.44 million shares valued at over $102 million. The medical device company reported strong quarterly earnings, beating estimates with $1.21 EPS and a 7.9% increase in revenue to $1.08 billion, while also issuing positive fiscal 2026 EPS guidance. Analyst sentiment for COO is mixed, with a consensus "Hold" rating and a price target of $81.36.
Cooper Companies Inc (COO) Stock News Today
This page provides current stock information for Cooper Companies Inc (COO), including its latest stock price, market capitalization, and P/E ratio. It indicates that more news and analysis for the company's stock is expected soon. The page also features a general disclaimer about investment risks.
The Cooper Companies, Inc. (NASDAQ:COO) Receives Consensus Recommendation of "Hold" from Analysts
The Cooper Companies, Inc. (NASDAQ:COO) has received a consensus "Hold" recommendation from seventeen analysts, with an average 12-month price target of $81.36. The company recently reported strong quarterly results, exceeding EPS and revenue estimates, and provided positive fiscal 2026 EPS guidance. Despite mixed recent analyst actions, institutional investors have been actively trading shares, and the company maintains a market capitalization of $14.30 billion.
Cooper Companies Inc (COO) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Cooper Companies Inc (COO), focusing on its current price momentum, support and resistance levels, and various technical indicators and moving averages. It highlights that COO's stock is trading between a resistance level of 76.18 and a support level of 69.42, suitable for range-bound swing trading. The analysis presents a mixed signal, with some indicators suggesting a buy and others a sell or neutral stance, and concludes that the overall signal based on moving averages and other technical indicators is Neutral.
This Contact Lens Stock Looks Ready to Rally
The article suggests that Cooper Cos., a contact lens manufacturer, is poised for a rally, potentially driven by the sale of a surgical unit and activist investor involvement. The long-term demand for contact lenses is projected to increase significantly due to a rise in nearsightedness globally, with estimates suggesting half the world will be myopic by 2050. This trend underscores a favorable market outlook for companies like Cooper Cos.
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors, with four new appointments effective August 5, 2026, at the request of majority owner Bausch Health Companies Inc. The company also reaffirmed its full-year 2026 guidance for revenue between $5.440 billion and $5.540 billion and Adjusted EBITDA excluding Acquired IPR&D between $1.025 billion and $1.075 billion. This follows a strong second-quarter performance with 9% revenue growth and significant margin expansion.
The Cooper Companies (COO) Upgraded to Buy: Here's What You Should Know
The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in its earnings estimates. This upgrade is significant because a company's changing earnings picture is a strong indicator of future stock price movement. The company's earnings estimates for the fiscal year ending October 2026 show no year-over-year change, but analysts have steadily raised estimates by 0.5% over the past three months.
Cooper Companies Inc (COO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cooper Companies Inc (COO), highlighting its current earnings forecast score of 7.58 and ranking within the Healthcare Equipment & Supplies industry. It details analyst ratings, target prices, and expected revenue and EPS for upcoming periods, indicating a "Buy" trend from most analysts. The report also includes peer comparisons and answers frequently asked questions regarding the company's financial outlook.
Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?
Henry Schein, Inc. (HSIC) recently hit a new 52-week high of $92.18, with shares up 2.6% over the past month and 17.9% year-to-date. The company has consistently beaten earnings estimates, reporting strong EPS and revenue growth. With a Zacks Rank of #2 (Buy) and favorable valuation metrics, analysts suggest there might still be room for the stock to appreciate further.
JANA Partners Management LP Has $254.91 Million Stock Position in The Cooper Companies, Inc. $COO
JANA Partners Management LP increased its stake in The Cooper Companies (NASDAQ:COO) by 1.3% in the first quarter, bringing its total holdings to 3.57 million shares valued at approximately $254.9 million. The medical device company exceeded quarterly expectations with $1.21 EPS and $1.08 billion in revenue, and analysts currently have a "Hold" rating on the stock with a consensus target price of $81.36.
Bank of Nova Scotia Has $1.95 Million Stake in The Cooper Companies, Inc. $COO
Bank of Nova Scotia significantly reduced its stake in The Cooper Companies by 88.2% in the first quarter, selling over 200,000 shares but still retaining shares worth approximately $1.95 million. Despite this, other major institutional investors increased their holdings, with institutional ownership collectively at 24.39%. Cooper Companies surpassed its quarterly earnings and revenue estimates, maintaining a consensus "Hold" rating from analysts.
First Trust Advisors LP Sells 32,742 Shares of The Cooper Companies, Inc. $COO
First Trust Advisors LP reduced its stake in The Cooper Companies (NASDAQ:COO) by 21.4% in the first quarter, selling 32,742 shares and retaining 120,148 shares valued at approximately $8.6 million. The medical device company reported strong quarterly earnings of $1.21 per share, beating estimates, with revenue rising 7.9% year-over-year to $1.08 billion. Despite positive earnings, analyst sentiment remains mixed, with a "Hold" consensus rating and an average price target slightly above the current stock price.
‘Myopia Can Hide in Plain Sight’: CAO Urges Child Eye Exams
The Canadian Association of Optometrists (CAO) has launched a digital awareness campaign titled "Myopia Can Hide in Plain Sight" to stress the importance of regular comprehensive eye exams for children. The campaign, supported by industry sponsors Alcon and CooperVision, aims to combat the rising prevalence of myopia and other eye conditions by promoting early detection, with recommended exams starting as early as six to nine months of age. Optometrists highlight that children often don't realize they have vision problems, making parental vigilance and professional screenings crucial for ensuring clear vision and preventing serious complications later in life.
Clear Channel Outdoor stock hits 52-week high at 2.44 USD
Clear Channel Outdoor Holdings Inc. stock reached a new 52-week high of $2.44, representing a 137.25% increase over the past year. This performance reflects strong investor confidence, though the stock is currently considered overvalued. The company's strategic initiatives and operational improvements have likely contributed to this upward trend, as noted by analysts and recent market adjustments.
CooperCompanies Announces Release Date for Third Quarter 2026
CooperCompanies announced it will release its third quarter 2026 financial results on Thursday, August 28, 2026, after the market closes. The company will also host a conference call and webcast to discuss the results, providing investors and interested parties with an opportunity to review its performance.
CooperCompanies schedules Sept. 9 results call at 5 p.m. ET
CooperCompanies (Nasdaq: COO) announced it will release its third quarter 2026 financial results on Wednesday, September 9, 2026, at 4:15 PM ET, followed by a conference call at 5:00 PM ET to discuss the results and current corporate developments. A webcast and replay will be available on its investor relations website. The announcement includes historical context of past events and their stock reactions, noting that this scheduling notice itself does not contain results.
Cooper Companies Inc (COO) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article presents a risk assessment for Cooper Companies Inc (COO), highlighting its current risk score and beta value. The company ranks 22 out of 199 in the Healthcare Equipment & Supplies industry with a beta of 0.88, suggesting it is less volatile than the overall market. The analysis also details various volatility, return, and liquidity metrics, including maximum drawdown, Sharpe Ratio, and average turnover rate.
COO|Cooper Companies Inc|Price:72.090|Chg%:+1.800
This article provides a detailed company profile for Cooper Companies Inc (COO), a global medical device company specializing in contact lenses and women's healthcare. It covers the company's business segments, key products, financial data including market cap and P/E, and a list of company executives and their shareholdings. The report also addresses FAQs regarding top shareholders, institutional holdings, and the biggest revenue source.
Healthcare Stocks With Less Litigation Risk After The JandJ Talc Settlement
The Johnson & Johnson talc settlement has prompted investors to re-evaluate litigation risk in healthcare stocks. This article examines three large-cap healthcare companies—Cooper Companies (COO), Envista Holdings (NVST), and Centene (CNC)—highlighting their potential appeal due to less direct exposure to significant litigation risks. It also delves into their financial positions, market challenges, and growth prospects.
Cooper Companies Inc (COO) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis of Cooper Companies Inc (COO), noting its current valuation score of 6.74, placing it 172nd out of 199 in the Healthcare Equipment & Supplies industry. It highlights COO's current P/E ratio of 34.65, which is significantly below its recent high but above its recent low. The article also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Cooper Companies Inc (COO) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Cooper Companies Inc (COO) shareholder structure, listing major shareholders and institutional holdings. It includes data on top investment firms, various shareholder types, and historical institutional shareholding trends with reporting periods and changes in shares held. The report also lists related ETFs that hold COO.
Cooper Companies Inc (COO) Institutional Confidence
The article reports on the institutional confidence score for Cooper Companies Inc (COO), which stands at 10.00, ranking 1st in its industry. Institutional shareholding decreased by 3.95% quarter-over-quarter, with Al Gore being the largest institutional shareholder. The data also lists key institutional shareholders and their recent activity.
Cooper Companies Inc (COO) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of Cooper Companies Inc (COO) dividends and stock splits. It details cash dividend payouts since July 2020, showing a consistent gross dividend of USD 0.03 per share, and also notes a 1-to-4 stock split that occurred on December 07, 2023.
The Cooper Companies’ Q2 2026 Earnings: What to Expect
The Cooper Companies (COO) is set to report its Q2 2026 earnings, with analysts expecting a slight increase in diluted EPS to $1.11. Despite outperforming EPS estimates in the past four quarters, COO's stock has underperformed the broader market due to concerns over slowing growth and below-average returns on invested capital. Analysts currently maintain a "Moderate Buy" rating with a potential upside of 15.3%.
Cooper Companies, Inc. Revenue Breakdown – FWB:CP60
This article provides a revenue breakdown for Cooper Companies, Inc. (FWB:CP60), highlighting its top-performing segment, CooperVision, which generated €2.38 billion last year. The United States was the largest contributor to revenue, accounting for €1.78 billion. The company's total revenue for the last year was €3.55 billion.
Cooper Companies Inc (COO) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cooper Companies Inc (COO), highlighting its current earnings forecast score of 7.43 and ranking within the Healthcare Equipment & Supplies industry. It includes analyst ratings, target prices, and anticipated EPS and revenue growth. The consensus among 18 analysts is a "Buy" rating for the stock.
COO|Cooper Companies Inc|Price:70.310|Chg%:+0.080
Cooper Companies Inc. (COO) is trading at $70.310, showing a slight increase of 0.11%. The company, a global medical device firm, is considered fairly valued with strong fundamentals and high growth potential. Analysts have rated it as a "Buy" with a target price of $83.49, suggesting an 18.88% upside.
The Cooper Companies, Inc. $COO Position Lowered by California Public Employees Retirement System
California Public Employees Retirement System (CalPERS) reduced its stake in The Cooper Companies (NASDAQ: COO) by 15.1% in the first quarter of 2026, selling 60,441 shares and retaining 338,750 shares valued at approximately $24.2 million. Despite this reduction by CalPERS, other institutional investors significantly increased their holdings in COO during the same period. The company reported strong financial results, beating analyst expectations with $1.21 EPS on $1.08 billion in revenue, and analysts hold a consensus "Hold" rating with an average price target of $81.85.
CooperCompanies stock trades steadily as contact lens growth supports earnings
CooperCompanies stock demonstrates stable fundamentals, with fiscal 2024 revenue and earnings primarily driven by its CooperVision contact lens division and continued investments in CooperSurgical. The company's financial performance highlights strong demand for ophthalmic and women's health products, particularly in daily disposable and specialty contact lenses, alongside growth in fertility solutions. This diversification across eye care and women's health products underpins its market position as a significant medical device firm.
Cooper Companies, Inc. Revenue Breakdown – GETTEX:CP60
This article details the revenue breakdown for Cooper Companies, Inc. (GETTEX:CP60). Last year, the company generated €3.55 billion in revenue, with its top-performing segment, CooperVision, contributing €2.38 billion. The United States was the largest regional contributor, accounting for €1.78 billion.
The Cooper Companies’ Q2 2026 Earnings: What to Expect
The Cooper Companies (COO) is a global medical device company specializing in vision care and women's health. Analysts anticipate COO to report diluted EPS of $1.11 for Q2 2026, slightly up from the previous year, continuing a trend of surpassing Wall Street estimates. Despite a 4.3% stock decline over the past year, analysts maintain a "Moderate Buy" rating with a target price suggesting a 15.3% potential upside.
CooperCompanies stock trades steadily as contact lens growth supports earnings
CooperCompanies' stock remains stable, driven by increased revenue from its CooperVision (contact lenses) and CooperSurgical (women's health) divisions. The company's fiscal 2025 results show a 7% year-over-year revenue growth to $3.1 billion, with robust operating margins and strong cash flow supporting ongoing investment and product development. Investors view CooperCompanies as a steady compounder in the medical device sector, benefiting from the sustained demand for its core products.
CooperCompanies stock steadies as investors weigh Vision and fertility growth
CooperCompanies' stock is influenced by a combination of its stable Vision Care segment and its growing fertility solutions business. The company generates over $3 billion in revenue, with CooperVision focusing on contact lenses and CooperSurgical providing fertility and women's health products. Investors analyze revenue growth, operating margins, EPS, and free cash flow to assess the company's valuation and market positioning in the healthcare sector.
CooperCompanies stock trades steadily as vision care growth supports earnings
CooperCompanies' stock performance is buoyed by consistent revenue growth in its vision care segment, particularly driven by contact lens demand, and robust cash generation. The fiscal 2025 results highlight strong contributions from CooperVision and CooperSurgical, along with maintained operating margins and a healthy balance sheet. Investors are observing the balance between organic growth and cash flows as the company continues to invest in innovation and market expansion.
The Cooper Companies, Inc. (COO) Stock Analysis: Unpacking A 13.92% Potential Upside
The Cooper Companies, Inc. (COO) is a healthcare sector player with a market cap of $13.99 billion, known for CooperVision and CooperSurgical. Analysts project a potential 13.92% upside from the current trading price of $71.71, with 10 buy ratings and an average target of $81.69. The stock shows robust revenue growth, a stable momentum from technical indicators, and a focus on reinvestment over dividends.
CooperCompanies stock trades steadily as contact lens growth supports earnings
CooperCompanies' stock is performing steadily due to solid demand for specialty contact lenses, reflected in higher revenue and operating profit, even amidst foreign exchange and inflation challenges. The company's focus on innovative eye care and women's health products, coupled with disciplined capital allocation and R&D investment, underpins its growth trajectory within the competitive medical device sector. Strong free cash flow enables continued investment in manufacturing, digital tools, and strategic acquisitions, while also supporting shareholder distributions.
CooperCompanies stock trades steadily as contact lens demand supports revenue growth
CooperCompanies stock is consistently trading well due to steady demand for its contact lenses and women's health products. The company's recent quarterly results show increased revenue and earnings, driven by investments in specialty lenses and fertility solutions. Its strategy focuses on long-term value creation by balancing growth investments with disciplined capital allocation, supported by a strong financial structure and continuous innovation.
CooperCompanies stock trades steady as contact lens demand supports earnings momentum
CooperCompanies stock demonstrates stable demand and earnings momentum, driven by its CooperVision (contact lenses) and CooperSurgical (women's health) divisions. The company reported double-digit revenue growth in the last fiscal year, supported by specialty contact lenses and increased procedure volumes in women's health, alongside robust gross and operating margins, contributing to healthy EPS growth. Its balanced capital allocation strategy, focusing on organic investments and strategic acquisitions, reinforces its position as a significant player in specialized medical devices, with the stock reflecting a multi-year record of sustained growth.
The Cooper Companies, Inc. Stock 12‑Month Price Target Cut to $81.25, Implies 11% Upside
The average 12-month price target for The Cooper Companies, Inc. (COO) stock has been reduced from $81.83 to $81.25, according to 12 analysts, implying an 11% potential upside from its July 16 closing price. Despite the cut, the consensus rating from 17 analysts remains a "Buy," with 12 Buy ratings, 5 Holds, and no Sells.
CooperCompanies stock trades steady as recent earnings highlight growth in contact lenses and women’s health
CooperCompanies' stock performance is buoyed by strong revenue and earnings growth, primarily driven by its CooperVision contact lenses and CooperSurgical women's health segments. The company maintains profitability and cash generation through product innovation, geographic diversification, and a strategic acquisition approach, appealing to investors looking for both growth potential and defensive characteristics in the medical devices sector. Despite competition and valuation considerations, its diversified product portfolio addressing persistent healthcare needs provides a stable earnings base.
CooperCompanies Releases 2025 Corporate Sustainability Report With Scope 3 Emissions Disclosure
CooperCompanies has released its 2025 Corporate Sustainability Report, which for the first time includes disclosure of Scope 3 greenhouse gas emissions, enhancing transparency in its sustainability reporting. The report highlights the company's commitment to people and the planet, showcased through innovations in vision care and women's health, and adherence to leading sustainability frameworks like SASB Standards and TCFD. Al White, president and CEO, emphasizes that these achievements reflect the global team's dedication to customers and patients.
